L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Henan Cancer Hospital
Send
Updated on 19 February 2024
See if I qualify
cancer
measurable disease
blood pregnancy test

Summary

Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy

Details
Condition Advanced Solid Tumor
Age 18-70 years
Treatment liquid tumor infiltrating lymphocytes
Clinical Study IdentifierNCT04268108
SponsorHenan Cancer Hospital
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Expected lifespan is over 3 months
malignant tumors diagnosed by pathological examination
Imaging examination is at advanced stage with at least one measurable lesion
Ineffective or resistant to previous anti-PD-1 therapy
ECOG score 0-2
Adequate organ function
No other serious diseases that conflict with this protocol
Women of childbearing age must check for a negative blood pregnancy test within 7 days, and subjects of childbearing age must use appropriate contraception during the test and within 3 months
witten informed consent from the patients

Exclusion Criteria

Severe infectious disease within 4 weeks before enrollment
Active hepatitis B or C virus or HIV infection
Severe autoimmune disease or immunodeficiency disease
Severe allergies
Severe mental disorder
Systematically used a large amount of glucocorticoids within 4 weeks before enrollment
With severe heart, liver, kidney insufficiency, diabetes and other diseases
Participation in other clinical studies in the past 3 months or having been treated with other gene products
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
measurable disease
blood pregnancy test

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.